Landscape of the clinical development of China innovative anti-lung cancer drugs
Even today, lung cancer remains one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Throughout the past decades, remarkable advances have been made in the research and development of anti-lung cancer drugs in China. Since the first registered Chines...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Pathogenesis and Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S294971322200009X |
| _version_ | 1797753923440738304 |
|---|---|
| author | Yuankai Shi |
| author_facet | Yuankai Shi |
| author_sort | Yuankai Shi |
| collection | DOAJ |
| description | Even today, lung cancer remains one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Throughout the past decades, remarkable advances have been made in the research and development of anti-lung cancer drugs in China. Since the first registered Chinese clinical trial on May 2, 2006, many potent anti-lung cancer drugs have been developed and approved by the China Food and Drug Administration and the National Medical Product Administration of China. Among them, the most advance were observed in the development of targeted agents and immunotherapeutic agents such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) icotinib, aumolertinib, and furmonertinib, anaplastic lymphoma kinase (ALK)-TKI ensartinib, programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) camrelizumab, sintilimab, and tislelizumab, and programmed cell death-ligand 1 (PD-L1) mAb sugemalimab, which have made huge breakthrough in recent years. Some other investigational innovative drug also demonstrated promising efficacy and acceptable safety profiles. Results from clinical studies on these China innovative drugs have led to changes in clinical practice guidelines and considerably improved the outcomes for patients with lung cancer. Thus, in this review, we aim to provide further insight into the clinical development and achievement of China innovative anti-lung cancer drugs. |
| first_indexed | 2024-03-12T17:24:59Z |
| format | Article |
| id | doaj.art-e2783c538ea04a3eaccc37b563be2911 |
| institution | Directory Open Access Journal |
| issn | 2949-7132 |
| language | English |
| last_indexed | 2024-03-12T17:24:59Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Pathogenesis and Therapy |
| spelling | doaj.art-e2783c538ea04a3eaccc37b563be29112023-08-05T05:18:34ZengElsevierCancer Pathogenesis and Therapy2949-71322023-01-01116775Landscape of the clinical development of China innovative anti-lung cancer drugsYuankai Shi0Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, ChinaEven today, lung cancer remains one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Throughout the past decades, remarkable advances have been made in the research and development of anti-lung cancer drugs in China. Since the first registered Chinese clinical trial on May 2, 2006, many potent anti-lung cancer drugs have been developed and approved by the China Food and Drug Administration and the National Medical Product Administration of China. Among them, the most advance were observed in the development of targeted agents and immunotherapeutic agents such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) icotinib, aumolertinib, and furmonertinib, anaplastic lymphoma kinase (ALK)-TKI ensartinib, programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) camrelizumab, sintilimab, and tislelizumab, and programmed cell death-ligand 1 (PD-L1) mAb sugemalimab, which have made huge breakthrough in recent years. Some other investigational innovative drug also demonstrated promising efficacy and acceptable safety profiles. Results from clinical studies on these China innovative drugs have led to changes in clinical practice guidelines and considerably improved the outcomes for patients with lung cancer. Thus, in this review, we aim to provide further insight into the clinical development and achievement of China innovative anti-lung cancer drugs.http://www.sciencedirect.com/science/article/pii/S294971322200009XLung cancerChinaAnticancer drugsDrug development |
| spellingShingle | Yuankai Shi Landscape of the clinical development of China innovative anti-lung cancer drugs Cancer Pathogenesis and Therapy Lung cancer China Anticancer drugs Drug development |
| title | Landscape of the clinical development of China innovative anti-lung cancer drugs |
| title_full | Landscape of the clinical development of China innovative anti-lung cancer drugs |
| title_fullStr | Landscape of the clinical development of China innovative anti-lung cancer drugs |
| title_full_unstemmed | Landscape of the clinical development of China innovative anti-lung cancer drugs |
| title_short | Landscape of the clinical development of China innovative anti-lung cancer drugs |
| title_sort | landscape of the clinical development of china innovative anti lung cancer drugs |
| topic | Lung cancer China Anticancer drugs Drug development |
| url | http://www.sciencedirect.com/science/article/pii/S294971322200009X |
| work_keys_str_mv | AT yuankaishi landscapeoftheclinicaldevelopmentofchinainnovativeantilungcancerdrugs |